Literature DB >> 7819092

Multiple myeloma: why does the disease escape from plateau phase?

D E Joshua1, R D Brown, J Gibson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7819092     DOI： 10.1111/j.1365-2141.1994.tb05102.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

Review 1.  Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients?

Authors:  J Bladé; J Esteve
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

Review 2.  Management of renal dysfunction in multiple myeloma.

Authors:  Sandeep R Pandit; David H Vesole
Journal:  Curr Treat Options Oncol       Date:  2003-06

Review 3.  Relapsed multiple myeloma.

Authors:  S Pandit; D H Vesole
Journal:  Curr Treat Options Oncol       Date:  2001-06

4.  Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance.

Authors:  C Bryant; H Suen; R Brown; S Yang; J Favaloro; E Aklilu; J Gibson; P J Ho; H Iland; P Fromm; N Woodland; N Nassif; D Hart; D E Joshua
Journal:  Blood Cancer J       Date:  2013-09-13       Impact factor: 11.037
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.